Medical - Distribution
Compare Stocks
2 / 10Stock Comparison
MCK vs CAH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
MCK vs CAH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution |
| Market Cap | $98.11B | $46.36B |
| Revenue (TTM) | $397.96B | $250.55B |
| Net Income (TTM) | $4.34B | $1.56B |
| Gross Margin | 3.4% | 3.7% |
| Operating Margin | 1.3% | 0.9% |
| Forward P/E | 20.5x | 19.1x |
| Total Debt | $7.39B | $9.35B |
| Cash & Equiv. | $5.69B | $3.87B |
MCK vs CAH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| McKesson Corporation (MCK) | 100 | 504.8 | +404.8% |
| Cardinal Health, In… (CAH) | 100 | 360.2 | +260.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MCK vs CAH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MCK is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 375.1% 10Y total return vs CAH's 175.5%
- 16.2% revenue growth vs CAH's -1.9%
CAH carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 0.03, yield 1.0%
- Lower volatility, beta 0.03, current ratio 0.94x
- Beta 0.03, yield 1.0%, current ratio 0.94x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs CAH's -1.9% | |
| Value | Lower P/E (19.1x vs 20.5x) | |
| Quality / Margins | 1.1% margin vs CAH's 0.6% | |
| Stability / Safety | Beta 0.03 vs MCK's 0.04 | |
| Dividends | 1.0% yield, 20-year raise streak, vs MCK's 0.3% | |
| Momentum (1Y) | +31.0% vs MCK's +13.7% | |
| Efficiency (ROA) | 5.3% ROA vs CAH's 2.8%, ROIC 5.4% vs 33.8% |
MCK vs CAH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MCK vs CAH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MCK leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $398.0B annually — 1.6x CAH's $250.5B. Profitability is closely matched — net margins range from 1.1% (MCK) to 0.6% (CAH).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $398.0B | $250.5B |
| EBITDAEarnings before interest/tax | $5.8B | $3.2B |
| Net IncomeAfter-tax profit | $4.3B | $1.6B |
| Free Cash FlowCash after capex | $10.1B | $4.4B |
| Gross MarginGross profit ÷ Revenue | +3.4% | +3.7% |
| Operating MarginEBIT ÷ Revenue | +1.3% | +0.9% |
| Net MarginNet income ÷ Revenue | +1.1% | +0.6% |
| FCF MarginFCF ÷ Revenue | +2.5% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.4% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.2% | -19.5% |
Valuation Metrics
CAH leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 30.5x trailing earnings, CAH trades at a 2% valuation discount to MCK's 31.1x P/E. On an enterprise value basis, CAH's 16.9x EV/EBITDA is more attractive than MCK's 19.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $98.1B | $46.4B |
| Enterprise ValueMkt cap + debt − cash | $99.8B | $51.8B |
| Trailing P/EPrice ÷ TTM EPS | 31.14x | 30.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.53x | 19.08x |
| PEG RatioP/E ÷ EPS growth rate | 0.80x | — |
| EV / EBITDAEnterprise value multiple | 19.93x | 16.91x |
| Price / SalesMarket cap ÷ Revenue | 0.27x | 0.21x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | 18.77x | 25.06x |
Profitability & Efficiency
MCK leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | — |
| ROA (TTM)Return on assets | +5.3% | +2.8% |
| ROICReturn on invested capital | +5.4% | +33.8% |
| ROCEReturn on capital employed | +30.5% | +19.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $1.7B | $5.5B |
| Cash & Equiv.Liquid assets | $5.7B | $3.9B |
| Total DebtShort + long-term debt | $7.4B | $9.3B |
| Interest CoverageEBIT ÷ Interest expense | 25.04x | 6.38x |
Total Returns (Dividends Reinvested)
Evenly matched — MCK and CAH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $43,011 today (with dividends reinvested), compared to $34,031 for CAH. Over the past 12 months, CAH leads with a +31.0% total return vs MCK's +13.7%. The 3-year compound annual growth rate (CAGR) favors CAH at 34.6% vs MCK's 30.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -2.6% | -3.7% |
| 1-Year ReturnPast 12 months | +13.7% | +31.0% |
| 3-Year ReturnCumulative with dividends | +121.2% | +144.1% |
| 5-Year ReturnCumulative with dividends | +330.1% | +240.3% |
| 10-Year ReturnCumulative with dividends | +375.1% | +175.5% |
| CAGR (3Y)Annualised 3-year return | +30.3% | +34.6% |
Risk & Volatility
CAH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than MCK's 0.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAH currently trades 84.3% from its 52-week high vs MCK's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.04x | 0.03x |
| 52-Week HighHighest price in past year | $999.00 | $233.60 |
| 52-Week LowLowest price in past year | $637.00 | $137.75 |
| % of 52W HighCurrent price vs 52-week peak | +80.2% | +84.3% |
| RSI (14)Momentum oscillator 0–100 | 27.7 | 38.1 |
| Avg Volume (50D)Average daily shares traded | 690K | 1.6M |
Analyst Outlook
CAH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates MCK as "Buy" and CAH as "Buy". Consensus price targets imply 26.7% upside for CAH (target: $250) vs 25.7% for MCK (target: $1007). For income investors, CAH offers the higher dividend yield at 1.04% vs MCK's 0.34%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1006.50 | $249.67 |
| # AnalystsCovering analysts | 31 | 33 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +1.0% |
| Dividend StreakConsecutive years of raises | 17 | 20 |
| Dividend / ShareAnnual DPS | $2.69 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.2% | +1.7% |
CAH leads in 3 of 6 categories (Valuation Metrics, Risk & Volatility). MCK leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.
MCK vs CAH: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MCK or CAH a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cardinal Health, Inc. (CAH) offers the better valuation at 30. 5x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MCK or CAH?
On trailing P/E, Cardinal Health, Inc.
(CAH) is the cheapest at 30. 5x versus McKesson Corporation at 31. 1x. On forward P/E, Cardinal Health, Inc. is actually cheaper at 19. 1x.
03Which is the better long-term investment — MCK or CAH?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +330.
1%, compared to +240. 3% for Cardinal Health, Inc. (CAH). Over 10 years, the gap is even starker: MCK returned +375. 1% versus CAH's +175. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MCK or CAH?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus McKesson Corporation's 0. 04β — meaning MCK is approximately 27% more volatile than CAH relative to the S&P 500.
05Which is growing faster — MCK or CAH?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MCK or CAH?
McKesson Corporation (MCK) is the more profitable company, earning 0.
9% net margin versus 0. 7% for Cardinal Health, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus 1. 0% for CAH. At the gross margin level — before operating expenses — CAH leads at 3. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MCK or CAH more undervalued right now?
On forward earnings alone, Cardinal Health, Inc.
(CAH) trades at 19. 1x forward P/E versus 20. 5x for McKesson Corporation — 1. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 26. 7% to $249. 67.
08Which pays a better dividend — MCK or CAH?
All stocks in this comparison pay dividends.
Cardinal Health, Inc. (CAH) offers the highest yield at 1. 0%, versus 0. 3% for McKesson Corporation (MCK).
09Is MCK or CAH better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 0% yield, +175. 5% 10Y return). Both have compounded well over 10 years (CAH: +175. 5%, MCK: +375. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MCK and CAH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock. CAH pays a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.